Patents by Inventor Steven Weitman

Steven Weitman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110097345
    Abstract: This invention relates to a method of treatment and dosing regimen for treating disease, such as cancer and mammalian tumors, wherein therapy with a cytotoxic drug is suitable, by the administration of an antibody-toxin conjugate, such as a maytansinoid toxin, by infusion at an initial infusion rate of 1 mg/min or lower on a schedule selected from the group consisting of: (1) an amount of at least about 90 mg/m2 on day 1 and day 8, every three weeks; (2) at least an amount of about 30 mg/m2 on day 1, day 2 and day 3, every three weeks; (3) at least an amount of about 45 mg/m2 on day 1, day 8, and day 15, every 4 weeks; and (4) at least an amount of about 45 mg/m2 on day 1, day 8 and day 15, every 3 weeks.
    Type: Application
    Filed: October 21, 2010
    Publication date: April 28, 2011
    Applicant: IMMUNOGEN INC.
    Inventors: John LAMBERT, James J. O'LEARY, Joanne Elizabeth Sarah SCHINDLER, Steven WEITMAN, Albert QIN
  • Publication number: 20050153274
    Abstract: A method of using Raman imaging microscopy to evaluate drug actions in living cells is disclosed. Specifically the invention describes the methods of using Raman imaging microscopy to detect drug uptake, distribution, binding, and metabolism in a single cell, and to study drug pharmacokinetics at the cellular level. The method involves measuring the Raman image of both the drug and the cell. Control images and post-treatment images of the cell were studied. Ratio images were calculated and the requisite information was obtained from a study of the intensity of the bright areas in the ratio images.
    Type: Application
    Filed: December 2, 2004
    Publication date: July 14, 2005
    Inventors: Jian Ling, Steven Weitman, Michael Miller